Is Exelixis a Buyout Target Again?
The most recent clinical trial results may have put Exelixis back on the map as a potential buyout.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 258Top Health Care Earnings for the Week Ahead
Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
4 Large Cap Biotech Stocks to Buy Before Earnings
A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.
Has Teladoc Peaked or Just Pulled Back After a Hot IPO?
ThinkstockTeladoc, Inc. (NYSE: TDOC) was nothing short of a very hot initial public offering back at the start of July. After creeping higher and higher, Teladoc shares have finally pulled back almost $2.00 from…
Huge Biotech Index Rebalance Means Massive Buy Orders for 5 Stocks
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.
NantKwest Sets Price Range for IPO
NantKwest has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
UnitedHealth Q2 Earnings Beat Fails to Impress
UnitedHealth reported better-than-expected second-quarter financial results Thursday before the markets opened.
Is Celgene Transforming Itself With Mergers and Pacts?
Celgene and Receptos announced Tuesday that they had signed a definitive agreement in which the former will acquire the latter in a deal worth roughly $7.2 billion.
Why Aetna Is Now a Bargain
Argus thinks the sell-off in Aetna stock following the Humana merger announcement on July 3 presents a buying opportunity.
Is T2 Biosystems Really Worth 50% More?
T2 Biosystems was reiterated as Buy at Janney Capital, and the firm said that it sees a fair value estimate of $25.00 for this stock.
ProNai Therapeutics Sets Price for IPO
ProNai Therapeutics has set the price for its initial public offering (IPO) that values it up to roughly $158 million.
Why Teva Pharmaceutical Bid for Mylan May Go Hostile
Teva could be about to enter the largest generic market by prescription in the world, which may tip the scales in its favor when it comes to wooing Mylan shareholders.
BioCardia Sets Price For IPO
ThinkstockBioCardia, Inc. filed an amended S-1 form with the Securities and Exchange Commission (SEC) regarding its initial public offering. In this filing the company gave its expected price range as $12 to $14 for about…
Why Biogen Is Now a Buy on Weakness
Merrill Lynch sees Biogen returning to these heightened levels, with its pipeline acting as the primary catalyst.
3 Top Big Pharmaceutical Stocks With Upcoming Catalysts
A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for investors now.